A Phase 1 interventional study of Xeruborbactam and Cefiderocol in Bacterial Infections, sponsored by Qpex Biopharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Bacterial Infections by Shionogi — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Shionogi.
Among the 10 studies in Bacterial Infections by Shionogi, this one is one of 3 that started in 2024, is one of 9 in phase 1, and was the 9th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →None of the 10 studies in Bacterial Infections by Shionogi is open now. The open studies under Bacterial Infections, anywhere →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 53 across the 9 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Qpex Biopharma, Inc., one of the names counted as Shionogi. Under that name alone:
Qpex Biopharma, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Bacterial Infections by Shionogi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
Qpex Biopharma, Inc. is developing xeruborbactam, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases in combination with a beta-lactam antibiotic.
Cefiderocol is a cephalosporin antibiotic approved in the US for the treatment of complicated urinary tract infections including pyelonephritis, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered single fixed dose of Xeruborbactam Administered single fixed dose of Cefiderocol Administered single fixed dose of a combination of Xeruborbactam and Cefiderocol.
Drug: Xeruborbactam · Drug: Cefiderocol · Drug: Xeruborbactam/Cefiderocol
Administered multiple fixed doses of Xeruborbactam
Drug: Xeruborbactam
Administered multiple fixed doses of Cefiderocol
Drug: Cefiderocol
Administered multiple fixed doses of a combination of Cefiderocol and Xeruborbactam.
Drug: Xeruborbactam/Cefiderocol
Administered multiple fixed volumes of a placebo comparator
Drug: Dextrose 5% in water
Administered single fixed volume of a placebo comparator
Drug: Dextrose 5% in water
Experimental
Also known as: QPX7728
Experimental
Drug pages: Xeruborbactam · Cefiderocol
A combination of Xeruborbactam and Cefiderocol.
Placebo
The incidence and nature of treatment emergent adverse events (TEAE)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Number of patients with changes from baseline in safety parameters
Summarized by cohort
Time frame: up to day 17 or up to day 21
Maximum plasma concentration (Cmax)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Time to maximum plasma concentration (Tmax)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Area under the plasma concentration versus time curve (AUC)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Terminal elimination half-life (t1/2,z)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Terminal elimination rate constant (λz)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Total clearance (CL)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Renal clearance (CLR)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Fraction of dose excreted in urine (Feu)
Summarized by cohort
Time frame: up to day 17 or up to day 21
Plan to share: No
Ran from Sep 2024 to primary completion in Oct 2025, 13 months.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 13 months is above that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xeruborbactam · Cefiderocol